3 Psychiatry Headlines You Missed in June 2026
· chelsie derman
AI Briefing
- • ADHD therapy faces regulatory setback, delaying FDA approval process.
- • Psychedelic shows rapid response in treating Major Depressive Disorder (MDD).
- • TMS technology moves into patients' homes for convenient treatment.
Source Summary
From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.
Advertisement